HSPA5 and plasma cell myeloma: Consistent with our findings, Met can repress GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib [15], and inhibit 2DG-induced autophagy to sensitize 2DG in prostate cancer cells [32].